Patrys Vision - to become the world leader in developing novel therapies for patients with cancer and other diseases, including natural human antibody-based therapies for the treatment of lung, pancreatic and gastric cancers.

Patrys – the natural human antibody based company

Patrys Limited (ASX: PAB) is an Australian public company committed to the development of novel treatments for cancer and other diseases.

The company has the world-wide, exclusive rights to technologies developed over 25 collective years of research and development that allow the capture, development and production of natural human antibodies for potential therapeutic applications.

Several antibodies that form Patrys' deep product pipeline have been successfully trialled in animal models of human lung, pancreatic, gastric and colon cancers.

Patrys has in place drug development collaborations with three large pharmaceutical companies.

In addition to its internal drug development projects and existing collaborations, Patrys has acquired a substantial preferred equity holding in Acceptys, Inc., an American company developing the platform natural human antibody technology for the treatment of infectious diseases including, Hepatitis B and Malaria.

Patrys' commercial strategy is to progress the internal development of lead product candidates while drawing benefits from partnerships and collaborations aimed at developing other candidates in the company's deep product pipeline.

The company has filed a broad range of patent applications to protect its antibodies, the antibody-producing cell lines, molecular targets and technologies.